NASDAQ:KLRS Kalaris Therapeutics (KLRS) Stock Price, News & Analysis $3.20 0.00 (0.00%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$3.20 0.00 (0.00%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Kalaris Therapeutics Stock (NASDAQ:KLRS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Kalaris Therapeutics alerts:Sign Up Key Stats Today's Range$3.04▼$3.2350-Day Range$3.16▼$4.8252-Week Range$3.03▼$11.88Volume234,394 shsAverage Volume63,626 shsMarket Capitalization$76.18 millionP/E RatioN/ADividend YieldN/APrice Target$18.75Consensus RatingModerate Buy Company Overview Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for retinal vascular diseases and other serious eye disorders. Its research programs are aimed at addressing diseases in which abnormal blood-vessel growth or leakage can impair vision. The company’s activities include the discovery and clinical development of investigational ophthalmic medicines intended to improve outcomes for patients with retinal conditions. Kalaris Therapeutics has not yet established a broad portfolio of marketed products, and its principal programs remain in development. Publicly available information about the company’s broader operating history, geographic reach and leadership is limited. Kalaris Therapeutics is based in the United States and serves the global biopharmaceutical market through its research and clinical-development activities.AI Generated. May Contain Errors. Read More Kalaris Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScoreKLRS MarketRank™: Kalaris Therapeutics scored higher than 55% of companies evaluated by MarketBeat, and ranked 290th out of 895 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingModerate Buy Consensus RatingKalaris Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 6 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialKalaris Therapeutics has a consensus price target of $18.75, representing about 485.9% upside from its current price of $3.20.Amount of Analyst CoverageKalaris Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Kalaris Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Earnings GrowthEarnings for Kalaris Therapeutics are expected to remain at ($1.99) per share in the coming year.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kalaris Therapeutics is -1.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kalaris Therapeutics is -1.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKalaris Therapeutics has a P/B Ratio of 0.76. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.56% of the float of Kalaris Therapeutics has been sold short.Short Interest Ratio / Days to CoverKalaris Therapeutics has a short interest ratio ("days to cover") of 7.05.Change versus previous monthShort interest in Kalaris Therapeutics has recently decreased by 12.04%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKalaris Therapeutics does not currently pay a dividend.Dividend GrowthKalaris Therapeutics does not have a long track record of dividend growth. News and Social Media1.3 / 5News SentimentN/A Search Interest3 people have searched for KLRS on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Kalaris Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Kalaris Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders68.10% of the stock of Kalaris Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions66.05% of the stock of Kalaris Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Kalaris Therapeutics' insider trading history. Receive KLRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kalaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. KLRS Stock News HeadlinesKalaris Therapeutics (NASDAQ:KLRS) Cut to Sell at Wall Street ZenSeptember 13, 2026 | americanbankingnews.comKalaris to Present at Morgan Stanley 24th Annual Global Healthcare ConferenceAugust 31, 2026 | globenewswire.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.September 21 at 1:00 AM | Porter & Company (Ad)Analysts Offer Insights on Healthcare Companies: Airsculpt Technologies (AIRS), Biohaven Ltd. (BHVN) and Kalaris Therapeutics (KLRS)August 15, 2026 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Mereo Biopharma Group Plc (MREO) and Kalaris Therapeutics (KLRS)August 13, 2026 | theglobeandmail.comKalaris Therapeutics, Inc.: Kalaris Reports Second Quarter 2026 Financial Results and Provides Business UpdatesAugust 11, 2026 | finanznachrichten.deKalaris Reports Second Quarter 2026 Financial Results and Provides Business UpdatesAugust 11, 2026 | finance.yahoo.comKalaris Therapeutics, Inc. (KLRS)August 5, 2026 | finance.yahoo.comSee More Headlines KLRS Stock Analysis - Frequently Asked Questions How have KLRS shares performed this year? Kalaris Therapeutics' stock was trading at $8.44 on January 1st, 2026. Since then, KLRS shares have decreased by 62.1% and is now trading at $3.20. How were Kalaris Therapeutics' earnings last quarter? Kalaris Therapeutics Inc. (NASDAQ:KLRS) issued its quarterly earnings data on Tuesday, August, 11th. The company reported ($0.48) EPS for the quarter, topping the consensus estimate of ($0.50) by $0.02. Who are Kalaris Therapeutics' major shareholders? Kalaris Therapeutics' top institutional shareholders include ADAR1 Capital Management LLC (0.42%), BlackRock Inc. (0.23%), Pale Fire Capital SE (0.17%) and Stonepine Capital Management LLC (0.13%). View institutional ownership trends. How do I buy shares of Kalaris Therapeutics? Shares of KLRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/11/2026Today9/21/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 KLRS's financial health is in the Red zone, according to TradeSmith. KLRS has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:KLRS CIK1754068 Webwww.kalaristx.com Phone(650) 249-2727FaxN/AEmployees110Year FoundedN/APrice Target and Rating Average Price Target for Kalaris Therapeutics$18.75 High Price Target$25.00 Low Price Target$14.00 Potential Upside/Downside+485.9%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($2.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$43.44 million Net MarginsN/A Pretax MarginN/A Return on Equity-71.71% Return on Assets-42.95% Debt Debt-to-Equity RatioN/A Current Ratio10.98 Quick Ratio10.98 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.21 per share Price / Book0.76Miscellaneous Outstanding Shares23,805,000Free Float7,594,000Market Cap$76.18 million OptionableN/A Beta0.22 10 Best Stocks to Own - Fall 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:KLRS) was last updated on 9/21/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kalaris Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kalaris Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
